RECENT NOTES / RESEARCH, SHARING & LIFE
What’s been happening?
Research, sharing, and life.
New papers, things to share, and photographs from along the way. Methods and results live in Research; longer thoughts go in the Journal.
RESEARCH / SHARING / LIFE
A few things to keep a note of.
- Research
PepDDG accepted at NeurIPS 2026. ↗
PepDDG combines complementary energy, geometry and evolutionary-compatibility signals to rank single-point mutations in a peptide chain, given its wild-type binding mode. The research page covers the method, results and limitations.
Read the research ↗ - Sharing
miniR’s first notebook entry: Where the Cursor Lands. ↗
miniR’s first lab note is on the site. It moves from a workbench for research agents to knowledge notes, with a little room for the sea in Richard’s photographs. Written by Richard’s AI assistant.
Read the journal entry ↗ - Life
Beyond the lab: a few pages from the photo album. ↗
A few photographs from Altay, Karon Beach in Phuket, and Chaka Salt Lake.
Browse the album ↗ - Sharing
Team Innovation Award in NIH/NICHD Data Challenge. ↗
Ruochi Zhang was a member of the Feng Ya team recognized for a fair-diagnosis proposal on maternal morbidity, demonstrated through stillbirth prediction.
Original source ↗ Team roster & project ↗
WORK / PUBLIC SOURCES
Work-related.
Public company reports, with their subject and original source.
- Work-related
Syneron Bio Announces Completion of $150 Million Series B Financing. ↗
Syneron Bio announced a $150 million Series B financing to advance its Synova macrocyclic peptide discovery platform and support its pipeline’s progression toward clinical development.
Original source ↗ - Work-related
Syneron Bio Closes Nearly $100M in Series A and A+ Rounds. ↗
Syneron Bio announced nearly $100 million across its Series A and A+ financing rounds. This is a company financing announcement.
Original source ↗ - Work-related
Syneron Bio Announces Strategic Collaboration with AstraZeneca. ↗
Syneron Bio announced a strategic collaboration with AstraZeneca on macrocyclic peptide therapies for chronic diseases. The announcement does not establish clinical efficacy.
Original source ↗